Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOULDER, Colo., March 26, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.  The team is excited to be joined by two of the Company’s CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.  An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.

About EDG-7500

EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2)

About Edgewise Therapeutics                                                                                

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission:  changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, XFacebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com 

Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-time-302412513.html

SOURCE Edgewise Therapeutics

Staff

Recent Posts

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development…

20 minutes ago

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…

2 hours ago

Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management

Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…

21 hours ago

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June…

2 days ago

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

3 days ago